Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle

被引:34
|
作者
Starzer, Angelika M. [1 ,2 ]
Preusser, Matthias [1 ,2 ]
Berghoff, Anna S. [1 ,2 ]
机构
[1] Med Univ Vienna, Dept Med 1, Div Oncol, Waehringer Guertel 18-20, Vienna, Austria
[2] Med Univ Vienna, Dept Med 1, Christian Doppler Lab Personalized Immunotherapy, Vienna, Austria
关键词
cancer-immunity cycle; immune checkpoint inhibitors; immune escape; immune resistance; PD-L1; solid cancer; CELL LUNG-CANCER; SYSTEMIC INFLAMMATORY RESPONSE; TUMOR-ASSOCIATED MACROPHAGES; T-CELLS; SURVIVAL; IMMUNOTHERAPY; PD-L1; IPILIMUMAB; COMBINATION; MULTICENTER;
D O I
10.1177/17588359221096219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities for various cancer types. However, despite the success in some entities, a significant fraction of patients does not respond to immune checkpoint inhibitors. A functioning cancer-immunity cycle is needed as the precondition for a clinically meaningful response to immune checkpoint inhibitors. It is assumed that only if each step of the cycle is activated and functioning properly, immune checkpoint inhibitors induce a meaningful immune response. However, an activated cancer-immunity cycle might not be present equally in each patient and cancer type. Ideally, treatment concepts should consider each single step of the cancer-immunity cycle and provide personalized treatment approaches, allowing the adaption to functioning and malfunctioning steps of the individual patient's specific cancer-immunity cycle. In the following review, we provide an overview of the single steps of the cancer-immunity cycle as well as the impact of malfunctioning steps on the generation of an effective tumor-specific immune response.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Autophagy in the cancer-immunity dialogue
    Yamazaki, Takahiro
    Bravo-San Pedro, Jose Manuel
    Galluzzi, Lorenzo
    Kroemer, Guido
    Pietrocola, Federico
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 169 : 40 - 50
  • [22] Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective
    Xiao, Yang
    Li, Yongsheng
    Zhao, Huakan
    MOLECULAR CANCER, 2024, 23 (01)
  • [23] Combination of tumor antigen drainage and immune activation to promote a cancer-immunity cycle against glioblastoma
    Xu, Han
    Zhao, Xiaomei
    Luo, Jincai
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2024, 81 (01)
  • [24] CD8+T cells in the cancer-immunity cycle
    Giles, Josephine R.
    Globig, Anna-Maria
    Kaech, Susan M.
    Wherry, E. John
    IMMUNITY, 2023, 56 (10) : 2231 - 2253
  • [25] A Comprehensive View of the Cancer-Immunity Cycle (CIC) in HPV-Mediated Cervical Cancer and Prospects for Emerging Therapeutic Opportunities
    Avila, Jonathan Pena
    Carvalho, Bruno Melo
    Coimbra, Eliane Campos
    CANCERS, 2023, 15 (04)
  • [26] Construction of novel magnetic systems for cancer immunotherapy via cancer-immunity cycle circuits
    Huang, Linghong
    Zhang, Quan
    Long, Jun
    Liu, Zonghua
    Sun, Xinyuan
    JOURNAL OF CONTROLLED RELEASE, 2025, 378 : 38 - 59
  • [27] RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond
    Ding, You-Peng
    Liu, Cui-Cui
    Yu, Ke-Da
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [28] Laser-Activatable In Situ Vaccine Enhances Cancer-Immunity Cycle
    Wang, Zhenyu
    You, Tingting
    Su, Qianyi
    Deng, Wenjia
    Li, Jiabao
    Hu, Saixiang
    Shi, Shengjun
    Zou, Zhaowei
    Xiao, Jisheng
    Duan, Xiaopin
    ADVANCED MATERIALS, 2023, 35 (52)
  • [29] Identification of TUBB2A as a Cancer-Immunity Cycle-Related Therapeutic Target in Triple-Negative Breast Cancer
    Li, Jia
    Yao, Jingchun
    Qi, Liqiang
    MOLECULAR BIOTECHNOLOGY, 2024, 66 (09) : 2467 - 2480
  • [30] Evoking the Cancer-immunity cycle by targeting the tumor-specific antigens in Cancer immunotherapy
    Guo, Xiaomeng
    Bai, Junqiang
    Wang, Xinmiao
    Guo, Shutian
    Shang, Zhengjun
    Shao, Zhe
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 154